The study, which assessed Humira (adalimumab) in patients with moderate to severe chronic plaque psoriasis, showed that nearly 70% of patients receiving Humira 40mg every other week experienced a 75% improvement in disease activity (known as a PASI 75 response) at week 60.
Furthermore, after 60 weeks, more than one-third of patients taking Humira 40mg every other week achieved PASI 90 – a measurement that correlates to at least a 90% reduction in disease activity and severity score. This score is considered a significant skin measurement that goes beyond what is typically highlighted in clinical trials.
Additionally, almost two-thirds of patients were determined to be ‘clear’ or ‘almost clear’ of their psoriasis, as measured by the physician’s global assessment, another measurement tool used by physicians to assess severity of disease.
“The study results are encouraging for patients whose lives continue to be negatively impacted by the effects of psoriasis,” said Dr Rebecca Hoffman, global project head for immunology development at Abbott. “As we move forward into phase III development, we are optimistic about the potential of Humira in the treatment of psoriasis.”
Humira has been approved by the FDA and EMEA for the treatment of rheumatoid arthritis, and clinical trials are currently underway evaluating its potential in other autoimmune diseases.